Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Lineage Cell Therapeutics Inc’s current trading price is -68.70% away from its 52-week high, while its distance from the 52-week low is -10.03%. The stock’s price range over this period has fluctuated between $0.56 and $1.61. The company, operating within the financial sector, had a trading volume of approximately 15.56 million for the day, which was noticeably higher than the average daily share volume of 0.61 million over the last 3 months.
The market performance of Lineage Cell Therapeutics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $1.61 on 03/28/24, while the lowest value for the same duration was $0.56 on 11/22/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -44.75% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 79.92M and boasts a workforce of 75 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.8988, with a change in price of -0.4146. Similarly, Lineage Cell Therapeutics Inc recorded 762,276 in trading volume during the last 100 days, posting a change of -45.14%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
Today’s raw stochastic average for Lineage Cell Therapeutics Inc over the last 50 days is 0.83%.This indicates a increase from the raw stochastic average of the past 20 days, which was 0.83%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 6.43% and 23.83%, respectively.
LCTX Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -53.77%. However, over the last six months, the performance has been stronger by -52.01%. The price of LCTX decreased -41.14% over the last 30 days. And in the last five days, it has fallen by -41.71%.
